Stocks Consumer discretionary POM
NASDAQ · Consumer discretionaryPOMDOCTOR Ltd (POM)
POMDOCTOR Ltd reported revenue of $57.2M in fiscal 2025. It posted a net loss of $30.4M. In fiscal 2025 capital spending exceeded operating cash flow by $21.4M. At December 31, 2025 it held $1.4M in cash against $11.7M of debt. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on May 14, 2026.
What POMDOCTOR Ltd does
POMDOCTOR Ltd is registered with the SEC under industry code SIC 5900 (Retail-Miscellaneous Retail). Its shares trade on NASDAQ under the ticker POM.
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $57.2M | -$30.4M | -$3.14 | -$21.4M |
Full financial statements: income, balance sheet and cash flow
Where POM ranks in Consumer discretionary
Latest SEC filings
What POMDOCTOR Ltd has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 24, 2026
- September 10, 2026
- September 4, 2026
- August 27, 2026
- August 10, 2026
- August 3, 2026
- July 28, 2026
- July 15, 2026
- July 13, 2026
- July 9, 2026
Questions about POM
What does POMDOCTOR Ltd do?
POMDOCTOR Ltd is registered with the SEC under industry code SIC 5900 (Retail-Miscellaneous Retail). Its shares trade on NASDAQ under the ticker POM.
Is POMDOCTOR Ltd profitable?
No. In fiscal 2025 it reported a net loss of $30.4M on revenue of $57.2M.
How much revenue does POMDOCTOR Ltd make?
In fiscal 2025 POMDOCTOR Ltd reported revenue of $57.2M.
When did POMDOCTOR Ltd last report?
Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on May 14, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from September 24, 2026.
Similar companies
Compare POM with
Follow POM
Get an email when POMDOCTOR Ltd files with the SEC: results, executive changes, material agreements and annual reports.
Follow POM: get an email when it filesWhere the numbers come from
Financial figures are the values POMDOCTOR Ltd tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.